Large gap with delayed quotes
|
Last quote
12/27/2024 -
17:20:00
|
Bid
12/27/2024 -
15:59:59
|
Bid Volume |
Ask
12/27/2024 -
15:59:59
|
Ask Volume |
|---|---|---|---|---|
|
1.21
-0.02
(
-1.63% )
|
1.21
|
33,300 |
1.22
|
29,400 |
Analysis date: 24.12.2024
Global Evaluation
Negativ
Negativ
The stock is classified in the negative zone since 11.10.2024.
Interest
Very weak
Very weak
Very weak interest since 02.08.2024.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 09.08.2024 at a price of 3.97.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, at its current price the stock is strongly overvalued.
MT Tech Trend
Negative
Negative
The forty day Medium Term Technical Trend is negative since 02.08.2024. The confirmed Technical Reverse point (Tech Reverse + 1.75%) is
4wk Rel Perf
-50.04%
-50.04%
The four week relative underperformance versus SP500 is 50.04%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
High
High
On average, the stock has a tendency to amplify the drops in the index by 2.97%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 6.08%.
Mkt Cap in $bn
0.10
0.10
With a market capitalization <$2bn, EDITAS MEDICINE is considered a small-cap stock.
G/PE Ratio
15.89
15.89
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
-0.78
-0.78
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
12.43%
12.43%
The annualized growth estimate is for the current year to 2026.
Avg. Nb analysts
16
16
Over the last seven weeks, an average of 16 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
170
170
For 1% of index variation, the stock varies on average by 1.70%.
Correlation
0.32
0.32
Stock movements are strongly independent of index variations.
Value at Risk
0.29
0.29
The value at risk is estimated at USD 0.29. The risk is therefore 24.01%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
21.12.2018
21.12.2018